10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

MYX (Mayne Pharma Group Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Mayne Pharma Group Ltd together

I guess you are interested in Mayne Pharma Group Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Mayne Pharma Group Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Mayne Pharma Group Ltd’s Price Targets

I'm going to help you getting a better view of Mayne Pharma Group Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Mayne Pharma Group Ltd

I send you an email if I find something interesting about Mayne Pharma Group Ltd.

1. Quick Overview

1.1. Quick analysis of Mayne Pharma Group Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Mayne Pharma Group Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
60.0%

What is your share worth?

Current worth
A$5.59
Expected worth in 1 year
A$-2.56
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-8.15
Return On Investment
-160.8%

For what price can you sell your share?

Current Price per Share
A$5.07
Expected price per share
A$4.14 - A$5.35
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Mayne Pharma Group Ltd (5 min.)




Live pricePrice per Share (EOD)
A$5.07
Intrinsic Value Per Share
A$-21.60 - A$-4.90
Total Value Per Share
A$-16.01 - A$0.69

2.2. Growth of Mayne Pharma Group Ltd (5 min.)




Is Mayne Pharma Group Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$297.7m$415.8m-$118.1m-39.7%

How much money is Mayne Pharma Group Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$114.2m-$207.4m$93.2m81.6%
Net Profit Margin-44.9%-172.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Mayne Pharma Group Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Mayne Pharma Group Ltd?

Welcome investor! Mayne Pharma Group Ltd's management wants to use your money to grow the business. In return you get a share of Mayne Pharma Group Ltd.

First you should know what it really means to hold a share of Mayne Pharma Group Ltd. And how you can make/lose money.

Speculation

The Price per Share of Mayne Pharma Group Ltd is A$5.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mayne Pharma Group Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mayne Pharma Group Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$5.59. Based on the TTM, the Book Value Change Per Share is A$-2.04 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.77 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mayne Pharma Group Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-1.41-27.7%-1.41-27.7%0.9218.2%-0.87-17.1%-1.01-19.9%-0.73-14.4%
Usd Book Value Change Per Share-1.34-26.4%-1.34-26.4%0.5110.0%-0.85-16.8%-0.90-17.8%0.244.7%
Usd Dividend Per Share0.000.0%0.000.0%0.367.0%0.244.7%0.295.7%0.8817.4%
Usd Total Gains Per Share-1.34-26.4%-1.34-26.4%0.8617.0%-0.61-12.1%-0.61-12.1%1.1222.1%
Usd Price Per Share3.09-3.09-2.88-2.05-1.32-1.01-
Price to Earnings Ratio-2.20--2.20-3.12-0.28-0.08-1.52-
Price-to-Total Gains Ratio-2.31--2.31-3.34-0.30-0.24-0.34-
Price to Book Ratio0.84-0.84-0.58-0.49-0.30-0.23-
Price-to-Total Gains Ratio-2.31--2.31-3.34-0.30-0.24-0.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.323385
Number of shares300
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.29
Usd Book Value Change Per Share-1.34-0.90
Usd Total Gains Per Share-1.34-0.61
Gains per Quarter (300 shares)-400.84-183.84
Gains per Year (300 shares)-1,603.34-735.35
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1603-1613349-1084-745
20-3207-3216698-2168-1480
30-4810-48191046-3252-2215
40-6413-64221395-4337-2950
50-8017-80251744-5421-3685
60-9620-96282093-6505-4420
70-11223-112312442-7589-5155
80-12827-128342790-8673-5890
90-14430-144373139-9757-6625
100-16033-160403488-10841-7360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%4.06.00.040.0%8.010.01.042.1%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%11.08.00.057.9%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%6.00.04.060.0%10.00.09.052.6%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%12.07.00.063.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Mayne Pharma Group Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.038-2.0380%0.771-364%-1.302-36%-1.378-32%0.363-662%
Book Value Per Share--5.5905.5900%7.629-27%6.692-16%8.480-34%9.484-41%
Current Ratio--1.4671.4670%1.780-18%1.362+8%1.639-11%1.795-18%
Debt To Asset Ratio--0.6030.6030%0.491+23%0.554+9%0.513+18%0.473+27%
Debt To Equity Ratio--1.5171.5170%0.966+57%1.259+20%1.086+40%1.091+39%
Dividend Per Share----0%0.545-100%0.367-100%0.443-100%1.345-100%
Enterprise Value---157043282.000-157043282.0000%-26968596.400-83%-265944809.467+69%-395852627.880+152%-438753288.040+179%
Eps---2.145-2.1450%1.410-252%-1.325-38%-1.537-28%-1.112-48%
Ev To Ebitda Ratio--1.3431.3430%0.139+865%3.088-57%6.083-78%2.100-36%
Ev To Sales Ratio---0.405-0.4050%-0.147-64%-1.486+267%-1.443+257%-1.386+243%
Free Cash Flow Per Share---0.445-0.4450%-3.154+609%-1.317+196%-0.606+36%-0.199-55%
Free Cash Flow To Equity Per Share---0.689-0.6890%-8.348+1111%-2.977+332%-1.662+141%0.833-183%
Gross Profit Margin--1.7501.7500%1.398+25%1.507+16%1.518+15%0.977+79%
Intrinsic Value_10Y_max---4.903----------
Intrinsic Value_10Y_min---21.597----------
Intrinsic Value_1Y_max---0.262----------
Intrinsic Value_1Y_min---1.546----------
Intrinsic Value_3Y_max---0.963----------
Intrinsic Value_3Y_min---5.208----------
Intrinsic Value_5Y_max---1.874----------
Intrinsic Value_5Y_min---9.459----------
Market Cap411916206.000+7%382667718.000382667718.0000%365883403.600+5%256287523.867+49%165228172.120+132%126121211.960+203%
Net Profit Margin---0.449-0.4490%-1.724+284%-1.321+194%-0.937+109%-0.512+14%
Operating Margin---0.478-0.4780%-1.412+196%-0.914+91%-0.726+52%-0.400-16%
Operating Ratio--1.3581.3580%2.016-33%1.716-21%1.435-5%1.156+17%
Pb Ratio0.907+7%0.8430.8430%0.577+46%0.485+74%0.304+177%0.234+259%
Pe Ratio-2.364-8%-2.196-2.1960%3.121-170%0.282-878%0.077-2950%1.516-245%
Price Per Share5.070+7%4.7104.7100%4.400+7%3.120+51%2.013+134%1.542+205%
Price To Free Cash Flow Ratio-11.391-8%-10.582-10.5820%-1.395-87%-4.230-60%-2.185-79%0.069-15529%
Price To Total Gains Ratio-2.487-8%-2.311-2.3110%3.343-169%0.304-860%0.245-1045%0.340-779%
Quick Ratio--1.2161.2160%1.745-30%1.256-3%1.311-7%1.322-8%
Return On Assets---0.152-0.1520%-0.254+66%-0.208+37%-0.164+7%-0.098-36%
Return On Equity---0.384-0.3840%-0.499+30%-0.460+20%-0.348-9%-0.193-50%
Total Gains Per Share---2.038-2.0380%1.316-255%-0.935-54%-0.935-54%1.708-219%
Usd Book Value--297720234.000297720234.0000%415822980.000-28%359578458.000-17%453548316.000-34%506022336.450-41%
Usd Book Value Change Per Share---1.336-1.3360%0.506-364%-0.854-36%-0.903-32%0.238-662%
Usd Book Value Per Share--3.6643.6640%5.001-27%4.387-16%5.559-34%6.217-41%
Usd Dividend Per Share----0%0.357-100%0.241-100%0.291-100%0.882-100%
Usd Enterprise Value---102941871.351-102941871.3510%-17677914.940-83%-174326822.605+69%-259481397.575+152%-287602780.310+179%
Usd Eps---1.406-1.4060%0.924-252%-0.869-38%-1.007-28%-0.729-48%
Usd Free Cash Flow---23704191.000-23704191.0000%-171935683.500+625%-71434205.000+201%-33051883.200+39%-10985852.250-54%
Usd Free Cash Flow Per Share---0.292-0.2920%-2.068+609%-0.863+196%-0.397+36%-0.130-55%
Usd Free Cash Flow To Equity Per Share---0.452-0.4520%-5.472+1111%-1.952+332%-1.090+141%0.546-183%
Usd Market Cap270011073.033+7%250838689.149250838689.1490%239836571.060+5%167996471.895+49%108307066.825+132%82672454.440+203%
Usd Price Per Share3.323+7%3.0873.0870%2.884+7%2.045+51%1.320+134%1.011+205%
Usd Profit---114209731.500-114209731.5000%-207412654.500+82%-168668453.000+48%-140689965.000+23%-88666600.800-22%
Usd Revenue--254432980.500254432980.5000%120340623.000+111%159261154.000+60%208009815.000+22%237446353.500+7%
Usd Total Gains Per Share---1.336-1.3360%0.863-255%-0.613-54%-0.613-54%1.120-219%
 EOD+5 -3MRQTTM+0 -0YOY+19 -213Y+22 -185Y+20 -2010Y+11 -29

3.3 Fundamental Score

Let's check the fundamental score of Mayne Pharma Group Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.364
Price to Book Ratio (EOD)Between0-10.907
Net Profit Margin (MRQ)Greater than0-0.449
Operating Margin (MRQ)Greater than0-0.478
Quick Ratio (MRQ)Greater than11.216
Current Ratio (MRQ)Greater than11.467
Debt to Asset Ratio (MRQ)Less than10.603
Debt to Equity Ratio (MRQ)Less than11.517
Return on Equity (MRQ)Greater than0.15-0.384
Return on Assets (MRQ)Greater than0.05-0.152
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Mayne Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.735
Ma 20Greater thanMa 505.086
Ma 50Greater thanMa 1005.631
Ma 100Greater thanMa 2006.269
OpenGreater thanClose5.010
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Mayne Pharma Group Ltd

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women's Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Fundamental data was last updated by Penke on 2025-07-01 03:39:08.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Mayne Pharma Group Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of -44.9% means that $-0.45 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -44.9%. The company is making a huge loss. -2
  • The TTM is -44.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-44.9%TTM-44.9%0.0%
TTM-44.9%YOY-172.4%+127.5%
TTM-44.9%5Y-93.7%+48.8%
5Y-93.7%10Y-51.2%-42.5%
4.3.1.2. Return on Assets

Shows how efficient Mayne Pharma Group Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • -15.2% Return on Assets means that Mayne Pharma Group Ltd generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mayne Pharma Group Ltd:

  • The MRQ is -15.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.2%TTM-15.2%0.0%
TTM-15.2%YOY-25.4%+10.1%
TTM-15.2%5Y-16.4%+1.1%
5Y-16.4%10Y-9.8%-6.6%
4.3.1.3. Return on Equity

Shows how efficient Mayne Pharma Group Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • -38.4% Return on Equity means Mayne Pharma Group Ltd generated $-0.38 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mayne Pharma Group Ltd:

  • The MRQ is -38.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -38.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-38.4%TTM-38.4%0.0%
TTM-38.4%YOY-49.9%+11.5%
TTM-38.4%5Y-34.8%-3.5%
5Y-34.8%10Y-19.3%-15.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Mayne Pharma Group Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Mayne Pharma Group Ltd is operating .

  • Measures how much profit Mayne Pharma Group Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • An Operating Margin of -47.8% means the company generated $-0.48  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mayne Pharma Group Ltd:

  • The MRQ is -47.8%. The company is operating very inefficient. -2
  • The TTM is -47.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-47.8%TTM-47.8%0.0%
TTM-47.8%YOY-141.2%+93.5%
TTM-47.8%5Y-72.6%+24.8%
5Y-72.6%10Y-40.0%-32.5%
4.3.2.2. Operating Ratio

Measures how efficient Mayne Pharma Group Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 1.36 means that the operating costs are $1.36 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.358. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.358. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.358TTM1.3580.000
TTM1.358YOY2.016-0.657
TTM1.3585Y1.435-0.076
5Y1.43510Y1.156+0.278
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Mayne Pharma Group Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.47 means the company has $1.47 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.467. The company is just able to pay all its short-term debts.
  • The TTM is 1.467. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.467TTM1.4670.000
TTM1.467YOY1.780-0.313
TTM1.4675Y1.639-0.172
5Y1.63910Y1.795-0.155
4.4.3.2. Quick Ratio

Measures if Mayne Pharma Group Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 1.22 means the company can pay off $1.22 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.216. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.216. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.216TTM1.2160.000
TTM1.216YOY1.745-0.529
TTM1.2165Y1.311-0.095
5Y1.31110Y1.322-0.011
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Mayne Pharma Group Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Mayne Pharma Group Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mayne Pharma Group Ltd to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.60 means that Mayne Pharma Group Ltd assets are financed with 60.3% credit (debt) and the remaining percentage (100% - 60.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 0.603. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.603. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.603TTM0.6030.000
TTM0.603YOY0.491+0.111
TTM0.6035Y0.513+0.090
5Y0.51310Y0.473+0.039
4.5.4.2. Debt to Equity Ratio

Measures if Mayne Pharma Group Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 151.7% means that company has $1.52 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mayne Pharma Group Ltd:

  • The MRQ is 1.517. The company is just able to pay all its debts with equity.
  • The TTM is 1.517. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.517TTM1.5170.000
TTM1.517YOY0.966+0.551
TTM1.5175Y1.086+0.431
5Y1.08610Y1.091-0.005
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mayne Pharma Group Ltd generates.

  • Above 15 is considered overpriced but always compare Mayne Pharma Group Ltd to the Drug Manufacturers - General industry mean.
  • A PE ratio of -2.20 means the investor is paying $-2.20 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is -2.364. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.196. Based on the earnings, the company is expensive. -2
  • The TTM is -2.196. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.364MRQ-2.196-0.168
MRQ-2.196TTM-2.1960.000
TTM-2.196YOY3.121-5.317
TTM-2.1965Y0.077-2.273
5Y0.07710Y1.516-1.439
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is -11.391. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -10.582. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.582. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.391MRQ-10.582-0.809
MRQ-10.582TTM-10.5820.000
TTM-10.582YOY-1.395-9.187
TTM-10.5825Y-2.185-8.397
5Y-2.18510Y0.069-2.253
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Mayne Pharma Group Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 0.84 means the investor is paying $0.84 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Mayne Pharma Group Ltd:

  • The EOD is 0.907. Based on the equity, the company is cheap. +2
  • The MRQ is 0.843. Based on the equity, the company is cheap. +2
  • The TTM is 0.843. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.907MRQ0.843+0.064
MRQ0.843TTM0.8430.000
TTM0.843YOY0.577+0.266
TTM0.8435Y0.304+0.539
5Y0.30410Y0.234+0.069
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Mayne Pharma Group Ltd.

4.8.2. Funds holding Mayne Pharma Group Ltd

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,143,177
Total Liabilities688,989
Total Stockholder Equity454,188
 As reported
Total Liabilities 688,989
Total Stockholder Equity+ 454,188
Total Assets = 1,143,177

Assets

Total Assets1,143,177
Total Current Assets460,593
Long-term Assets682,584
Total Current Assets
Cash And Cash Equivalents 110,068
Short-term Investments 39,210
Net Receivables 193,222
Inventory 74,629
Other Current Assets 43,464
Total Current Assets  (as reported)460,593
Total Current Assets  (calculated)460,593
+/-0
Long-term Assets
Property Plant Equipment 53,326
Long Term Investments 15,337
Intangible Assets 568,580
Long-term Assets Other 60,678
Long-term Assets  (as reported)682,584
Long-term Assets  (calculated)697,921
+/- 15,337

Liabilities & Shareholders' Equity

Total Current Liabilities313,938
Long-term Liabilities375,051
Total Stockholder Equity454,188
Total Current Liabilities
Short-term Debt 3,820
Accounts payable 20,874
Other Current Liabilities 289,244
Total Current Liabilities  (as reported)313,938
Total Current Liabilities  (calculated)313,938
+/-0
Long-term Liabilities
Long term Debt 31,641
Capital Lease Obligations 7,180
Long-term Liabilities Other 332,373
Long-term Liabilities  (as reported)375,051
Long-term Liabilities  (calculated)371,194
+/- 3,857
Total Stockholder Equity
Common Stock1,224,224
Retained Earnings -944,003
Accumulated Other Comprehensive Income 173,967
Total Stockholder Equity (as reported)454,188
Total Stockholder Equity (calculated)454,188
+/-0
Other
Capital Stock1,224,224
Cash and Short Term Investments 149,278
Common Stock Shares Outstanding 79,620
Current Deferred Revenue6,536
Liabilities and Stockholders Equity 1,143,177
Net Debt -71,247
Net Invested Capital 485,829
Net Working Capital 146,655
Property Plant and Equipment Gross 104,783
Short Long Term Debt Total 38,821



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
> Total Assets 
29
15,510
11,693
8,036
71,149
53,677
53,933
233,391
265,820
528,946
1,557,381
1,914,920
1,830,507
1,636,333
1,825,180
1,463,184
1,287,926
1,247,354
1,143,177
1,143,1771,247,3541,287,9261,463,1841,825,1801,636,3331,830,5071,914,9201,557,381528,946265,820233,39153,93353,67771,1498,03611,69315,51029
   > Total Current Assets 
0
15,453
11,648
8,013
32,529
18,838
23,255
61,909
65,895
156,820
1,108,650
429,003
480,767
471,946
490,947
416,528
511,618
553,629
460,593
460,593553,629511,618416,528490,947471,946480,767429,0031,108,650156,82065,89561,90923,25518,83832,5298,01311,64815,4530
       Cash And Cash Equivalents 
29
15,303
11,531
7,936
19,709
5,807
11,596
18,938
14,813
59,201
47,481
63,027
87,312
89,004
137,785
97,980
96,672
92,616
110,068
110,06892,61696,67297,980137,78589,00487,31263,02747,48159,20114,81318,93811,5965,80719,7097,93611,53115,30329
       Short-term Investments 
0
0
0
0
0
0
0
1,825
1,172
2,229
3,458
6,208
6,747
563
0
0
127,526
127,526
39,210
39,210127,526127,526005636,7476,2083,4582,2291,1721,8250000000
       Net Receivables 
0
80
47
39
5,999
5,697
3,821
24,622
29,805
64,657
123,716
232,716
252,715
256,580
195,908
183,283
268,241
194,887
193,222
193,222194,887268,241183,283195,908256,580252,715232,716123,71664,65729,80524,6223,8215,6975,9993947800
       Other Current Assets 
0
70
70
37
321
911
594
2,931
2,869
8,289
895,052
20,658
51,837
26,014
63,257
32,755
37,797
28,173
43,464
43,46428,17337,79732,75563,25726,01451,83720,658895,0528,2892,8692,9315949113213770700
   > Long-term Assets 
0
57
45
23
38,621
34,839
30,678
171,482
199,925
372,126
448,731
1,485,917
1,349,740
1,164,387
1,334,233
1,046,656
776,308
693,725
682,584
682,584693,725776,3081,046,6561,334,2331,164,3871,349,7401,485,917448,731372,126199,925171,48230,67834,83938,6212345570
       Property Plant Equipment 
0
57
45
23
21,047
21,457
22,224
55,036
53,409
59,597
84,449
189,272
230,051
236,034
238,244
221,595
225,855
51,482
53,326
53,32651,482225,855221,595238,244236,034230,051189,27284,44959,59753,40955,03622,22421,45721,0472345570
       Goodwill 
0
0
0
0
391
391
391
47,197
47,476
58,436
60,115
58,217
20,616
21,725
22,174
20,346
22,127
0
0
0022,12720,34622,17421,72520,61658,21760,11558,43647,47647,1973913913910000
       Long Term Investments 
0
0
0
0
0
0
0
0
4,076
0
0
0
0
0
0
0
0
0
15,337
15,3370000000004,07600000000
       Intangible Assets 
0
0
0
0
13,835
7,792
3,803
68,273
93,639
244,524
272,368
1,177,224
1,033,910
775,907
940,117
615,808
405,387
617,264
568,580
568,580617,264405,387615,808940,117775,9071,033,9101,177,224272,368244,52493,63968,2733,8037,79213,8350000
       Other Assets 
0
0
0
0
3,347
5,199
4,260
18,981
34,763
9,569
31,799
152,815
167,389
183,499
174,398
-302,376
-606,224
24,979
0
024,979-606,224-302,376174,398183,499167,389152,81531,7999,56934,76318,9814,2605,1993,3470000
> Total Liabilities 
7
996
255
332
45,600
29,503
23,333
112,502
106,546
206,744
1,181,160
602,496
595,350
622,258
782,867
691,605
730,806
612,994
688,989
688,989612,994730,806691,605782,867622,258595,350602,4961,181,160206,744106,546112,50223,33329,50345,6003322559967
   > Total Current Liabilities 
7
991
253
318
23,167
14,939
12,304
42,111
30,379
95,078
1,055,924
199,895
179,897
211,329
219,253
222,527
610,421
310,959
313,938
313,938310,959610,421222,527219,253211,329179,897199,8951,055,92495,07830,37942,11112,30414,93923,1673182539917
       Short-term Debt 
0
3
3
2
7,587
2,339
0
7,471
2,374
2,229
503
13,124
58
50,881
44,836
54,043
407,993
14,427
3,820
3,82014,427407,99354,04344,83650,8815813,1245032,2292,3747,47102,3397,5872330
       Short Long Term Debt 
0
0
0
0
0
0
0
0
48,030
61,756
76,834
13,011
374,190
50,861
44,836
51,158
405,367
10,810
0
010,810405,36751,15844,83650,861374,19013,01176,83461,75648,03000000000
       Accounts payable 
7
166
135
119
2,227
2,142
2,893
6,832
7,131
51,572
135,508
66,593
63,888
50,443
29,842
42,363
63,571
32,027
20,874
20,87432,02763,57142,36329,84250,44363,88866,593135,50851,5727,1316,8322,8932,1422,2271191351667
       Other Current Liabilities 
0
821
115
197
13,353
10,458
9,411
27,808
20,874
43,506
919,913
120,178
115,951
110,005
144,575
126,121
138,857
22,854
289,244
289,24422,854138,857126,121144,575110,005115,951120,178919,91343,50620,87427,8089,41110,45813,3531971158210
   > Long-term Liabilities 
0
6
2
14
22,433
14,564
11,029
70,391
76,167
111,666
125,236
402,601
415,453
410,929
563,614
469,078
120,385
302,035
375,051
375,051302,035120,385469,078563,614410,929415,453402,601125,236111,66676,16770,39111,02914,56422,43314260
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
62,754
76,331
327,122
374,132
318,501
353,211
292,776
5,673
33,078
0
033,0785,673292,776353,211318,501374,132327,12276,33162,754000000000
       Other Liabilities 
0
6
2
14
15,856
10,086
7,299
10,594
8,726
49,910
48,905
75,479
40,494
92,430
210,403
176,302
114,712
268,957
0
0268,957114,712176,302210,40392,43040,49475,47948,90549,9108,72610,5947,29910,08615,85614260
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
33,438
51,562
72,048
91,611
102,225
53,373
40,700
-491,283
-729,163
2,039
0
02,039-729,163-491,28340,70053,373102,22591,61172,04851,56233,43800000000
> Total Stockholder Equity
21
14,514
11,438
7,704
25,550
24,174
30,600
120,889
159,274
310,870
363,749
1,303,838
1,226,464
1,007,766
1,037,547
768,357
564,773
634,360
454,188
454,188634,360564,773768,3571,037,5471,007,7661,226,4641,303,838363,749310,870159,274120,88930,60024,17425,5507,70411,43814,51421
   Common Stock
30
15,908
15,869
15,869
29,649
31,870
32,016
118,302
137,498
255,834
263,161
1,130,404
1,131,761
1,140,008
1,238,584
1,238,537
1,238,537
1,233,692
1,224,224
1,224,2241,233,6921,238,5371,238,5371,238,5841,140,0081,131,7611,130,404263,161255,834137,498118,30232,01631,87029,64915,86915,86915,90830
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 
0
439
875
902
1,714
960
1,087
7,461
5,360
30,861
39,058
23,337
71,178
125,099
149,603
88,883
148,642
170,438
173,967
173,967170,438148,64288,883149,603125,09971,17823,33739,05830,8615,3607,4611,0879601,7149028754390
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
5,360
27,631
29,928
23,337
71,178
125,011
149,603
88,883
148,642
-463,922
0
0-463,922148,64288,883149,603125,01171,17823,33729,92827,6315,36000000000



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.




5.4. Cash Flows

Currency in AUD. All numbers in thousands.




5.5. Income Statements

Currency in AUD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue388,151
Cost of Revenue-169,624
Gross Profit218,527218,527
 
Operating Income (+$)
Gross Profit218,527
Operating Expense-357,590
Operating Income-139,063-139,063
 
Operating Expense (+$)
Research Development20,236
Selling General Administrative55,527
Selling And Marketing Expenses130,697
Operating Expense357,590206,460
 
Net Interest Income (+$)
Interest Income7,066
Interest Expense-34,501
Other Finance Cost-500
Net Interest Income-27,935
 
Pretax Income (+$)
Operating Income-139,063
Net Interest Income-27,935
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-190,087-88,039
EBIT - interestExpense = -219,886
-195,701
-139,732
Interest Expense34,501
Earnings Before Interest and Taxes (EBIT)-185,385-155,586
Earnings Before Interest and Taxes (EBITDA)-116,926
 
After tax Income (+$)
Income Before Tax-190,087
Tax Provision--21,468
Net Income From Continuing Ops-168,619-168,619
Net Income-174,233
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses434,255
Total Other Income/Expenses Net-51,02427,935
 

Technical Analysis of Mayne Pharma Group Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mayne Pharma Group Ltd. The general trend of Mayne Pharma Group Ltd is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mayne Pharma Group Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Mayne Pharma Group Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Mayne Pharma Group Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.31 < 5.31 < 5.35.

The bearish price targets are: 4.86 > 4.31 > 4.14.

Know someone who trades $MYX? Share this with them.👇

Mayne Pharma Group Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Mayne Pharma Group Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Mayne Pharma Group Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Mayne Pharma Group Ltd. The current macd is -0.13016086.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mayne Pharma Group Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Mayne Pharma Group Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Mayne Pharma Group Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Mayne Pharma Group Ltd Daily Moving Average Convergence/Divergence (MACD) ChartMayne Pharma Group Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Mayne Pharma Group Ltd. The current adx is 39.18.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Mayne Pharma Group Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Mayne Pharma Group Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Mayne Pharma Group Ltd. The current sar is 4.59304815.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Mayne Pharma Group Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Mayne Pharma Group Ltd. The current rsi is 45.74. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Mayne Pharma Group Ltd Daily Relative Strength Index (RSI) ChartMayne Pharma Group Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Mayne Pharma Group Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mayne Pharma Group Ltd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Mayne Pharma Group Ltd Daily Stochastic Oscillator ChartMayne Pharma Group Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Mayne Pharma Group Ltd. The current cci is -25.33904354.

Mayne Pharma Group Ltd Daily Commodity Channel Index (CCI) ChartMayne Pharma Group Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Mayne Pharma Group Ltd. The current cmo is -0.64029896.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Mayne Pharma Group Ltd Daily Chande Momentum Oscillator (CMO) ChartMayne Pharma Group Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Mayne Pharma Group Ltd. The current willr is -57.14285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Mayne Pharma Group Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Mayne Pharma Group Ltd Daily Williams %R ChartMayne Pharma Group Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Mayne Pharma Group Ltd.

Mayne Pharma Group Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Mayne Pharma Group Ltd. The current atr is 0.1966385.

Mayne Pharma Group Ltd Daily Average True Range (ATR) ChartMayne Pharma Group Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Mayne Pharma Group Ltd. The current obv is -4,029,621.

Mayne Pharma Group Ltd Daily On-Balance Volume (OBV) ChartMayne Pharma Group Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Mayne Pharma Group Ltd. The current mfi is 47.70.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Mayne Pharma Group Ltd Daily Money Flow Index (MFI) ChartMayne Pharma Group Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Mayne Pharma Group Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Mayne Pharma Group Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Mayne Pharma Group Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.735
Ma 20Greater thanMa 505.086
Ma 50Greater thanMa 1005.631
Ma 100Greater thanMa 2006.269
OpenGreater thanClose5.010
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Mayne Pharma Group Ltd with someone you think should read this too:
  • Are you bullish or bearish on Mayne Pharma Group Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mayne Pharma Group Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Mayne Pharma Group Ltd

I send you an email if I find something interesting about Mayne Pharma Group Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Mayne Pharma Group Ltd.

Receive notifications about Mayne Pharma Group Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.